25 XP   0   0   10

Nektar Therapeutics
Buy, Hold or Sell?

Let's analyse Nektar together

PenkeI guess you are interested in Nektar Therapeutics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Nektar Therapeutics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Nektar Therapeutics

I send you an email if I find something interesting about Nektar Therapeutics.

Quick analysis of Nektar (30 sec.)










What can you expect buying and holding a share of Nektar? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.69
Expected worth in 1 year
$-0.58
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-1.26
Return On Investment
-86.4%

For what price can you sell your share?

Current Price per Share
$1.46
Expected price per share
$1.09 - $2.19
How sure are you?
50%

1. Valuation of Nektar (5 min.)




Live pricePrice per Share (EOD)

$1.46

Intrinsic Value Per Share

$-19.86 - $10.50

Total Value Per Share

$-19.18 - $11.19

2. Growth of Nektar (5 min.)




Is Nektar growing?

Current yearPrevious yearGrowGrow %
How rich?$130.9m$461.3m-$279.3m-153.4%

How much money is Nektar making?

Current yearPrevious yearGrowGrow %
Making money-$69m-$92m$23m33.4%
Net Profit Margin-312.5%-405.5%--

How much money comes from the company's main activities?

3. Financial Health of Nektar (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#331 / 1007

Most Revenue
#215 / 1007

Most Profit
#927 / 1007

Most Efficient
#679 / 1007

What can you expect buying and holding a share of Nektar? (5 min.)

Welcome investor! Nektar's management wants to use your money to grow the business. In return you get a share of Nektar.

What can you expect buying and holding a share of Nektar?

First you should know what it really means to hold a share of Nektar. And how you can make/lose money.

Speculation

The Price per Share of Nektar is $1.46. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nektar.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nektar, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.69. Based on the TTM, the Book Value Change Per Share is $-0.32 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.43 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nektar.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.22-15.1%-0.36-24.9%-0.49-33.7%-0.55-38.0%-0.24-16.2%
Usd Book Value Change Per Share-0.15-10.4%-0.32-21.6%-0.43-29.6%-0.43-29.7%0.032.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.15-10.4%-0.32-21.6%-0.43-29.6%-0.43-29.7%0.032.0%
Usd Price Per Share0.57-0.61-3.66-13.46-20.16-
Price to Earnings Ratio-0.64--0.51--2.05--5.63--12.18-
Price-to-Total Gains Ratio-3.73--2.54--9.87--32.03-22.29-
Price to Book Ratio0.82-0.66-1.45-2.39--177.03-
Price-to-Total Gains Ratio-3.73--2.54--9.87--32.03-22.29-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.46
Number of shares684
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.32-0.43
Usd Total Gains Per Share-0.32-0.43
Gains per Quarter (684 shares)-215.82-296.46
Gains per Year (684 shares)-863.27-1,185.84
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-863-8730-1186-1196
20-1727-17360-2372-2382
30-2590-25990-3558-3568
40-3453-34620-4743-4754
50-4316-43250-5929-5940
60-5180-51880-7115-7126
70-6043-60510-8301-8312
80-6906-69140-9487-9498
90-7769-77770-10673-10684
100-8633-86400-11858-11870

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%4.036.00.010.0%7.0113.00.05.8%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%8.032.00.020.0%28.091.01.023.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%7.00.0113.05.8%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%8.032.00.020.0%28.091.01.023.3%

Fundamentals of Nektar

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-11 15:58:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Nektar Therapeutics.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nektar earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nektar to the Biotechnology industry mean.
  • A Net Profit Margin of -176.2% means that $-1.76 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nektar Therapeutics:

  • The MRQ is -176.2%. The company is making a huge loss. -2
  • The TTM is -312.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-176.2%TTM-312.5%+136.3%
TTM-312.5%YOY-405.5%+93.0%
TTM-312.5%5Y-389.9%+77.4%
5Y-389.9%10Y-256.9%-133.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-176.2%-207.2%+31.0%
TTM-312.5%-216.8%-95.7%
YOY-405.5%-282.4%-123.1%
5Y-389.9%-434.0%+44.1%
10Y-256.9%-584.8%+327.9%
1.1.2. Return on Assets

Shows how efficient Nektar is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nektar to the Biotechnology industry mean.
  • -10.6% Return on Assets means that Nektar generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nektar Therapeutics:

  • The MRQ is -10.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.6%TTM-13.9%+3.3%
TTM-13.9%YOY-10.8%-3.1%
TTM-13.9%5Y-9.4%-4.5%
5Y-9.4%10Y-6.4%-3.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.6%-13.2%+2.6%
TTM-13.9%-12.7%-1.2%
YOY-10.8%-11.5%+0.7%
5Y-9.4%-13.8%+4.4%
10Y-6.4%-15.5%+9.1%
1.1.3. Return on Equity

Shows how efficient Nektar is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nektar to the Biotechnology industry mean.
  • -32.1% Return on Equity means Nektar generated $-0.32 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nektar Therapeutics:

  • The MRQ is -32.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -35.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.1%TTM-35.9%+3.8%
TTM-35.9%YOY-20.0%-15.9%
TTM-35.9%5Y-17.7%-18.2%
5Y-17.7%10Y-83.7%+66.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.1%-16.7%-15.4%
TTM-35.9%-15.9%-20.0%
YOY-20.0%-14.7%-5.3%
5Y-17.7%-19.2%+1.5%
10Y-83.7%-20.0%-63.7%

1.2. Operating Efficiency of Nektar Therapeutics.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nektar is operating .

  • Measures how much profit Nektar makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nektar to the Biotechnology industry mean.
  • An Operating Margin of -128.4% means the company generated $-1.28  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nektar Therapeutics:

  • The MRQ is -128.4%. The company is operating very inefficient. -2
  • The TTM is -183.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-128.4%TTM-183.1%+54.7%
TTM-183.1%YOY-256.2%+73.1%
TTM-183.1%5Y-307.2%+124.1%
5Y-307.2%10Y-202.2%-105.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-128.4%-298.0%+169.6%
TTM-183.1%-238.5%+55.4%
YOY-256.2%-291.9%+35.7%
5Y-307.2%-485.6%+178.4%
10Y-202.2%-610.8%+408.6%
1.2.2. Operating Ratio

Measures how efficient Nektar is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.28 means that the operating costs are $2.28 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Nektar Therapeutics:

  • The MRQ is 2.284. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.512. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.284TTM2.512-0.228
TTM2.512YOY3.562-1.050
TTM2.5125Y4.051-1.540
5Y4.05110Y3.027+1.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2843.235-0.951
TTM2.5123.310-0.798
YOY3.5623.791-0.229
5Y4.0515.675-1.624
10Y3.0277.558-4.531

1.3. Liquidity of Nektar Therapeutics.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nektar is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.45 means the company has $6.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Nektar Therapeutics:

  • The MRQ is 6.450. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.752. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.450TTM7.752-1.302
TTM7.752YOY7.112+0.640
TTM7.7525Y8.480-0.727
5Y8.48010Y7.346+1.134
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4503.877+2.573
TTM7.7524.178+3.574
YOY7.1125.343+1.769
5Y8.4806.135+2.345
10Y7.3466.468+0.878
1.3.2. Quick Ratio

Measures if Nektar is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nektar to the Biotechnology industry mean.
  • A Quick Ratio of 11.49 means the company can pay off $11.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nektar Therapeutics:

  • The MRQ is 11.495. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 13.449. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.495TTM13.449-1.954
TTM13.449YOY12.240+1.209
TTM13.4495Y15.136-1.687
5Y15.13610Y12.730+2.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.4953.514+7.981
TTM13.4493.998+9.451
YOY12.2405.380+6.860
5Y15.1366.135+9.001
10Y12.7306.434+6.296

1.4. Solvency of Nektar Therapeutics.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nektar assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nektar to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.67 means that Nektar assets are financed with 67.1% credit (debt) and the remaining percentage (100% - 67.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nektar Therapeutics:

  • The MRQ is 0.671. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.621. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.671TTM0.621+0.050
TTM0.621YOY0.458+0.163
TTM0.6215Y0.393+0.228
5Y0.39310Y0.615-0.222
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6710.339+0.332
TTM0.6210.336+0.285
YOY0.4580.271+0.187
5Y0.3930.368+0.025
10Y0.6150.388+0.227
1.4.2. Debt to Equity Ratio

Measures if Nektar is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nektar to the Biotechnology industry mean.
  • A Debt to Equity ratio of 203.9% means that company has $2.04 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nektar Therapeutics:

  • The MRQ is 2.039. The company is just not able to pay all its debts with equity.
  • The TTM is 1.664. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.039TTM1.664+0.375
TTM1.664YOY0.849+0.815
TTM1.6645Y0.760+0.904
5Y0.76010Y7.883-7.123
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0390.388+1.651
TTM1.6640.403+1.261
YOY0.8490.340+0.509
5Y0.7600.430+0.330
10Y7.8830.463+7.420

2. Market Valuation of Nektar Therapeutics

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nektar generates.

  • Above 15 is considered overpriced but always compare Nektar to the Biotechnology industry mean.
  • A PE ratio of -0.64 means the investor is paying $-0.64 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nektar Therapeutics:

  • The EOD is -1.657. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.641. Based on the earnings, the company is expensive. -2
  • The TTM is -0.509. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.657MRQ-0.641-1.016
MRQ-0.641TTM-0.509-0.132
TTM-0.509YOY-2.053+1.544
TTM-0.5095Y-5.630+5.121
5Y-5.63010Y-12.182+6.552
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.657-2.281+0.624
MRQ-0.641-2.599+1.958
TTM-0.509-2.674+2.165
YOY-2.053-4.133+2.080
5Y-5.630-6.258+0.628
10Y-12.182-6.270-5.912
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nektar Therapeutics:

  • The EOD is -1.475. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.571. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.601. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.475MRQ-0.571-0.904
MRQ-0.571TTM-0.601+0.031
TTM-0.601YOY-2.170+1.569
TTM-0.6015Y-7.486+6.885
5Y-7.48610Y-15.136+7.650
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.475-2.903+1.428
MRQ-0.571-3.323+2.752
TTM-0.601-3.552+2.951
YOY-2.170-5.592+3.422
5Y-7.486-8.378+0.892
10Y-15.136-8.875-6.261
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nektar is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.82 means the investor is paying $0.82 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Nektar Therapeutics:

  • The EOD is 2.129. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.824. Based on the equity, the company is cheap. +2
  • The TTM is 0.660. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.129MRQ0.824+1.305
MRQ0.824TTM0.660+0.164
TTM0.660YOY1.453-0.793
TTM0.6605Y2.394-1.734
5Y2.39410Y-177.032+179.426
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1291.911+0.218
MRQ0.8242.116-1.292
TTM0.6602.097-1.437
YOY1.4532.885-1.432
5Y2.3943.556-1.162
10Y-177.0323.959-180.991
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Nektar Therapeutics.

3.1. Institutions holding Nektar Therapeutics

Institutions are holding 67.251% of the shares of Nektar Therapeutics.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Deep Track Capital, LP10.02080.34721840000000
2023-12-31Vanguard Group Inc6.55870.000212042873-18274-0.1515
2023-12-31Acadian Asset Management LLC4.25820.017178188041924162.523
2023-12-31PRIMECAP Management Company3.81320.00317001747-196236-2.7263
2023-09-30D. E. Shaw & Co LP3.33470.00386123024-3029297-33.0987
2023-12-31BlackRock Inc3.32440.00016104217-1580412-20.5659
2023-12-31Monaco Asset Management3.25320.99335973387116378624.1971
2023-09-30Citadel Advisors Llc3.06340.00075625000-4078652-42.0321
2023-12-31Renaissance Technologies Corp2.90030.00475325475181879451.8665
2023-12-31GSA Capital Partners LLP2.86240.249752557903414712185.4735
2023-09-30Jacobs Levy Equity Management, Inc.2.67120.01734904745342670.7036
2023-09-30TANG CAPITAL MANAGEMENT LLC2.14550.3311393960038000002722.063
2023-12-31Two Sigma Advisers, LLC1.67170.00413069542-679900-18.1334
2023-12-31Assenagon Asset Management SA1.34320.00372466267-369196-13.0207
2023-12-31Marshall Wace Asset Management Ltd1.29960.00232386241-549977-18.7308
2023-12-31Two Sigma Investments LLC1.18560.00282176981-618068-22.113
2023-12-31Geode Capital Management, LLC1.11080.00012039614842584.3091
2023-12-31Goldman Sachs Group Inc0.94090.0001172773870127468.3194
2023-12-31Millennium Management LLC0.86930.0004159614940558634.0667
2023-09-30Point72 Asset Management, L.P.0.82810.0026152057814977196551.9883
Total 57.45521.9844105497772+1992800+1.9%

3.2. Funds holding Nektar Therapeutics

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv3.18410.0003584657100
2023-12-31PRIMECAP Odyssey Aggressive Growth2.30550.0333423338000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.45780.0019267685700
2023-12-31PRIMECAP Odyssey Growth1.14220.01732097356-38300-1.7934
2023-12-31Vanguard Strategic Equity Inv0.82620.011151710300
2024-02-29Fidelity Extended Market Index0.57840.0021061973-5145-0.4821
2024-02-29BlackRock Advantage Small Cap Core Instl0.55850.02071025448-2878-0.2799
2024-03-29Schwab US Small-Cap ETF™0.44290.004581315200
2023-12-31Vanguard Strategic Small-Cap Equity Inv0.41570.02976330900
2024-02-29Vanguard Health Care ETF0.35050.002264355931360.4897
2023-09-30BlackRock Extended Mkt Composite0.29350.002353885100
2024-03-28Invesco FTSE RAFI US 1500 Small-Mid ETF0.28650.020652608200
2023-12-31Vanguard US Opportunities Ins USD Acc0.28370.0235521011-500-0.0959
2024-03-31BlackRock Extended Equity Market K0.25610.0034702721690.0359
2024-02-29Fidelity Total Market Index0.18120.000333266900
2023-12-31Vanguard Market Neutral I0.14220.029926112800
2024-02-29Delaware Healthcare I0.13960.023425638500
2024-02-29Fidelity Series Total Market Index0.13490.000324767400
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.12440.0022283407590149.7911
2024-03-31Blackrock Russell 2000 Alpha Tilts Fd A0.12420.022322801524081.0673
Total 13.22810.249824289135+34791+0.1%

3.3. Insider Transactions

Insiders are holding 0.822% of the shares of Nektar Therapeutics.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-20Howard W RobinSELL200330.68
2024-02-20Jonathan ZalevskySELL90140.68
2023-11-17Howard W RobinSELL198770.49
2023-11-17Jonathan ZalevskySELL96460.49
2023-09-18Myriam CuretSELL43590.69
2023-08-16Howard W RobinSELL199980.78
2023-08-16Jonathan ZalevskySELL97030.78
2023-06-14Roy A WhitfieldSELL300000.57
2023-05-16Howard W RobinSELL203610.72
2023-05-16Jonathan ZalevskySELL97910.72

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Nektar Therapeutics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.151-0.316+108%-0.431+185%-0.433+186%0.029-615%
Book Value Per Share--0.6860.959-29%2.468-72%4.568-85%3.077-78%
Current Ratio--6.4507.752-17%7.112-9%8.480-24%7.346-12%
Debt To Asset Ratio--0.6710.621+8%0.458+47%0.393+71%0.615+9%
Debt To Equity Ratio--2.0391.664+23%0.849+140%0.760+168%7.883-74%
Dividend Per Share----0%-0%-0%-0%
Eps---0.220-0.364+65%-0.492+124%-0.555+152%-0.237+8%
Free Cash Flow Per Share---0.248-0.255+3%-0.414+67%-0.434+75%-0.182-26%
Free Cash Flow To Equity Per Share---0.247-0.340+37%-0.412+66%-0.456+84%-0.004-99%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--10.502--------
Intrinsic Value_10Y_min---19.862--------
Intrinsic Value_1Y_max---0.472--------
Intrinsic Value_1Y_min---1.732--------
Intrinsic Value_3Y_max---0.256--------
Intrinsic Value_3Y_min---5.458--------
Intrinsic Value_5Y_max--1.360--------
Intrinsic Value_5Y_min---9.434--------
Market Cap268082280.000+60%107937600.000115798445.575-7%684356885.000-84%2476896894.115-96%3703152861.058-97%
Net Profit Margin---1.762-3.125+77%-4.055+130%-3.899+121%-2.569+46%
Operating Margin---1.284-1.831+43%-2.562+100%-3.072+139%-2.022+58%
Operating Ratio--2.2842.512-9%3.562-36%4.051-44%3.027-25%
Pb Ratio2.129+61%0.8240.660+25%1.453-43%2.394-66%-177.032+21584%
Pe Ratio-1.657-158%-0.641-0.509-21%-2.053+220%-5.630+778%-12.182+1800%
Price Per Share1.460+61%0.5650.610-7%3.663-85%13.465-96%20.155-97%
Price To Free Cash Flow Ratio-1.475-158%-0.571-0.601+5%-2.170+280%-7.486+1212%-15.136+2552%
Price To Total Gains Ratio-9.647-158%-3.733-2.541-32%-9.869+164%-32.032+758%22.292-117%
Quick Ratio--11.49513.449-15%12.240-6%15.136-24%12.730-10%
Return On Assets---0.106-0.139+32%-0.108+2%-0.094-11%-0.064-39%
Return On Equity---0.321-0.359+12%-0.200-38%-0.177-45%-0.837+161%
Total Gains Per Share---0.151-0.316+108%-0.431+185%-0.433+186%0.029-615%
Usd Book Value--130987000.000182044500.000-28%461370500.000-72%841994950.000-84%566585775.000-77%
Usd Book Value Change Per Share---0.151-0.316+108%-0.431+185%-0.433+186%0.029-615%
Usd Book Value Per Share--0.6860.959-29%2.468-72%4.568-85%3.077-78%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.220-0.364+65%-0.492+124%-0.555+152%-0.237+8%
Usd Free Cash Flow---47284000.000-48367750.000+2%-77420750.000+64%-80315700.000+70%-33802625.000-29%
Usd Free Cash Flow Per Share---0.248-0.255+3%-0.414+67%-0.434+75%-0.182-26%
Usd Free Cash Flow To Equity Per Share---0.247-0.340+37%-0.412+66%-0.456+84%-0.004-99%
Usd Market Cap268082280.000+60%107937600.000115798445.575-7%684356885.000-84%2476896894.115-96%3703152861.058-97%
Usd Price Per Share1.460+61%0.5650.610-7%3.663-85%13.465-96%20.155-97%
Usd Profit---42079000.000-69014000.000+64%-92049500.000+119%-102596200.000+144%-43898000.000+4%
Usd Revenue--23885000.00022530500.000+6%23013750.000+4%27580800.000-13%66239450.000-64%
Usd Total Gains Per Share---0.151-0.316+108%-0.431+185%-0.433+186%0.029-615%
 EOD+5 -3MRQTTM+20 -13YOY+20 -135Y+18 -1510Y+9 -24

4.2. Fundamental Score

Let's check the fundamental score of Nektar Therapeutics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.657
Price to Book Ratio (EOD)Between0-12.129
Net Profit Margin (MRQ)Greater than0-1.762
Operating Margin (MRQ)Greater than0-1.284
Quick Ratio (MRQ)Greater than111.495
Current Ratio (MRQ)Greater than16.450
Debt to Asset Ratio (MRQ)Less than10.671
Debt to Equity Ratio (MRQ)Less than12.039
Return on Equity (MRQ)Greater than0.15-0.321
Return on Assets (MRQ)Greater than0.05-0.106
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Nektar Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.485
Ma 20Greater thanMa 501.374
Ma 50Greater thanMa 1001.051
Ma 100Greater thanMa 2000.805
OpenGreater thanClose1.450
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -6,9071,226-5,681-769-6,45098-6,3526,43280



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets398,033
Total Liabilities267,046
Total Stockholder Equity130,987
 As reported
Total Liabilities 267,046
Total Stockholder Equity+ 130,987
Total Assets = 398,033

Assets

Total Assets398,033
Total Current Assets330,701
Long-term Assets67,332
Total Current Assets
Cash And Cash Equivalents 20,161
Short-term Investments 283,455
Net Receivables 2,252
Inventory 16,101
Other Current Assets 8,732
Total Current Assets  (as reported)330,701
Total Current Assets  (calculated)330,701
+/-0
Long-term Assets
Property Plant Equipment 36,863
Long Term Investments 25,825
Long-term Assets Other 4,644
Long-term Assets  (as reported)67,332
Long-term Assets  (calculated)67,332
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities51,269
Long-term Liabilities215,777
Total Stockholder Equity130,987
Total Current Liabilities
Short-term Debt 19,259
Accounts payable 9,848
Other Current Liabilities 22,162
Total Current Liabilities  (as reported)51,269
Total Current Liabilities  (calculated)51,269
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt98,517
Long-term Liabilities Other 117,260
Long-term Liabilities  (as reported)215,777
Long-term Liabilities  (calculated)215,777
+/-0
Total Stockholder Equity
Common Stock19
Retained Earnings -3,477,249
Accumulated Other Comprehensive Income 80
Other Stockholders Equity 3,608,137
Total Stockholder Equity (as reported)130,987
Total Stockholder Equity (calculated)130,987
+/-0
Other
Capital Stock19
Cash and Short Term Investments 303,616
Common Stock Shares Outstanding 191,040
Liabilities and Stockholders Equity 398,033
Net Debt 210,240
Net Invested Capital 130,987
Net Working Capital 279,432
Property Plant and Equipment Gross 123,761
Short Long Term Debt Total 230,401



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-301994-03-31
> Total Assets 
7,100
20,900
20,300
17,200
28,500
26,700
25,000
23,200
21,200
38,700
36,800
41,500
73,017
74,802
74,848
119,762
113,873
110,067
102,599
134,496
131,349
126,688
121,369
226,806
448,292
434,361
420,325
629,540
687,143
722,695
685,683
667,241
667,241
657,005
626,534
606,638
563,944
634,496
632,925
616,788
787,135
760,919
741,103
744,921
714,192
694,055
946,910
858,554
841,538
827,145
790,020
768,177
713,740
703,465
738,285
725,103
643,836
609,493
568,352
560,536
505,939
472,998
452,651
575,518
548,509
530,638
502,476
521,225
704,478
670,854
648,093
606,550
694,789
668,443
541,452
497,790
447,901
412,809
383,035
434,527
487,013
478,137
476,902
441,621
499,212
456,667
449,246
502,061
491,879
463,099
425,095
568,871
528,486
475,859
582,055
508,866
496,790
2,313,087
2,249,098
2,150,172
2,166,482
2,099,653
2,088,294
1,977,356
1,887,933
1,594,878
1,508,666
1,538,767
1,456,561
1,371,351
1,277,243
1,117,189
1,024,116
861,987
781,006
710,600
561,743
494,279
442,244
398,033
398,033442,244494,279561,743710,600781,006861,9871,024,1161,117,1891,277,2431,371,3511,456,5611,538,7671,508,6661,594,8781,887,9331,977,3562,088,2942,099,6532,166,4822,150,1722,249,0982,313,087496,790508,866582,055475,859528,486568,871425,095463,099491,879502,061449,246456,667499,212441,621476,902478,137487,013434,527383,035412,809447,901497,790541,452668,443694,789606,550648,093670,854704,478521,225502,476530,638548,509575,518452,651472,998505,939560,536568,352609,493643,836725,103738,285703,465713,740768,177790,020827,145841,538858,554946,910694,055714,192744,921741,103760,919787,135616,788632,925634,496563,944606,638626,534657,005667,241667,241685,683722,695687,143629,540420,325434,361448,292226,806121,369126,688131,349134,496102,599110,067113,873119,76274,84874,80273,01741,50036,80038,70021,20023,20025,00026,70028,50017,20020,30020,9007,100
   > Total Current Assets 
5,400
19,300
17,900
14,800
25,900
24,100
22,300
20,400
18,200
35,500
33,100
37,500
68,672
67,966
64,358
100,925
86,980
76,557
64,537
84,540
76,807
72,459
64,466
147,318
344,283
317,145
288,644
493,043
464,897
401,684
369,452
360,841
360,841
354,290
329,397
310,989
270,437
329,653
326,841
306,498
489,773
461,291
450,740
454,539
428,847
411,282
658,209
519,843
549,366
572,726
546,432
535,039
491,577
483,366
514,771
523,283
443,523
410,128
410,287
406,220
350,595
318,203
298,213
413,666
385,471
363,806
326,434
353,979
539,373
389,095
297,620
276,706
420,654
468,291
346,945
314,631
267,036
234,423
207,942
257,882
304,770
298,223
324,120
288,200
347,293
302,246
286,351
350,051
344,845
318,320
282,522
426,252
380,985
288,165
382,795
326,820
336,015
1,905,947
1,505,182
1,437,687
1,490,114
1,596,817
1,578,824
1,421,550
1,429,324
1,151,968
1,043,856
1,138,005
1,099,051
1,056,148
986,135
795,581
733,455
665,536
599,483
545,968
491,066
441,058
399,025
330,701
330,701399,025441,058491,066545,968599,483665,536733,455795,581986,1351,056,1481,099,0511,138,0051,043,8561,151,9681,429,3241,421,5501,578,8241,596,8171,490,1141,437,6871,505,1821,905,947336,015326,820382,795288,165380,985426,252282,522318,320344,845350,051286,351302,246347,293288,200324,120298,223304,770257,882207,942234,423267,036314,631346,945468,291420,654276,706297,620389,095539,373353,979326,434363,806385,471413,666298,213318,203350,595406,220410,287410,128443,523523,283514,771483,366491,577535,039546,432572,726549,366519,843658,209411,282428,847454,539450,740461,291489,773306,498326,841329,653270,437310,989329,397354,290360,841360,841369,452401,684464,897493,043288,644317,145344,283147,31864,46672,45976,80784,54064,53776,55786,980100,92564,35867,96668,67237,50033,10035,50018,20020,40022,30024,10025,90014,80017,90019,3005,400
       Cash And Cash Equivalents 
2,200
11,900
7,800
10,500
20,000
6,900
3,100
3,800
1,900
8,000
8,600
18,600
36,662
33,149
9,627
14,948
11,397
28,481
18,312
24,916
18,023
14,671
19,284
33,430
129,778
88,775
93,095
136,012
80,042
223,142
30,000
30,814
30,814
25,628
44,676
34,879
21,526
100,196
51,397
64,050
180,669
36,268
92,369
104,414
47,516
70,375
357,217
261,273
262,028
151,989
157,668
63,760
83,140
82,856
174,713
76,293
36,676
31,829
63,713
155,584
122,300
114,992
32,777
49,597
20,572
23,244
12,906
17,755
22,485
11,626
43,008
15,312
148,485
136,154
10,338
25,437
28,531
41,432
65,411
39,067
32,443
30,699
32,008
12,365
129,452
20,875
18,819
55,570
72,549
55,676
63,295
59,640
23,480
16,149
37,967
4,762
34,805
911,125
222,261
194,905
106,752
85,424
81,224
96,363
227,035
58,206
55,843
198,955
150,164
152,345
54,017
25,218
67,993
77,545
105,758
88,227
76,955
50,728
64,921
20,161
20,16164,92150,72876,95588,227105,75877,54567,99325,21854,017152,345150,164198,95555,84358,206227,03596,36381,22485,424106,752194,905222,261911,12534,8054,76237,96716,14923,48059,64063,29555,67672,54955,57018,81920,875129,45212,36532,00830,69932,44339,06765,41141,43228,53125,43710,338136,154148,48515,31243,00811,62622,48517,75512,90623,24420,57249,59732,777114,992122,300155,58463,71331,82936,67676,293174,71382,85683,14063,760157,668151,989262,028261,273357,21770,37547,516104,41492,36936,268180,66964,05051,397100,19621,52634,87944,67625,62830,81430,81430,000223,14280,042136,01293,09588,775129,77833,43019,28414,67118,02324,91618,31228,48111,39714,9489,62733,14936,66218,6008,6008,0001,9003,8003,1006,90020,00010,5007,80011,9002,200
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
31,123
28,020
48,032
85,225
72,443
45,824
44,552
57,946
55,553
43,618
39,077
104,755
205,940
220,672
187,819
348,829
373,839
162,525
323,382
313,542
313,542
310,272
268,877
259,090
229,986
208,075
252,793
221,917
286,741
389,003
334,544
314,326
353,787
308,132
263,111
214,928
217,488
323,931
323,940
394,880
315,187
323,933
277,931
406,060
375,954
342,078
280,803
223,410
202,999
179,311
242,901
346,614
341,386
314,976
290,396
298,177
496,157
351,280
223,479
225,856
233,624
296,720
308,939
251,757
207,664
160,453
118,139
197,959
251,628
245,737
204,635
225,459
171,353
233,785
249,000
253,374
215,776
219,178
190,216
329,462
335,043
249,398
314,600
291,370
261,854
912,683
1,198,149
1,140,445
1,281,913
1,429,955
1,414,448
1,228,499
1,118,847
980,191
900,163
862,941
887,152
847,720
867,063
708,737
599,032
541,771
440,629
416,750
379,872
358,704
307,737
283,455
283,455307,737358,704379,872416,750440,629541,771599,032708,737867,063847,720887,152862,941900,163980,1911,118,8471,228,4991,414,4481,429,9551,281,9131,140,4451,198,149912,683261,854291,370314,600249,398335,043329,462190,216219,178215,776253,374249,000233,785171,353225,459204,635245,737251,628197,959118,139160,453207,664251,757308,939296,720233,624225,856223,479351,280496,157298,177290,396314,976341,386346,614242,901179,311202,999223,410280,803342,078375,954406,060277,931323,933315,187394,880323,940323,931217,488214,928263,111308,132353,787314,326334,544389,003286,741221,917252,793208,075229,986259,090268,877310,272313,542313,542323,382162,525373,839348,829187,819220,672205,940104,75539,07743,61855,55357,94644,55245,82472,44385,22548,03228,02031,123000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
5,000
5,000
0
0
0
0
0
0
13,632
1,167
1,756
682
2,321
1,942
7,234
3,333
10,390
5,321
4,487
4,487
4,848
3,710
4,370
6,775
8,847
8,724
6,153
3,563
18,944
5,643
12,842
6,333
10,448
14,551
8,205
17,432
72,487
37,838
47,148
64,747
49,829
36,805
21,637
14,040
12,067
8,515
11,161
5,796
8,473
6,330
4,801
7,709
9,446
5,553
25,102
2,160
8,460
12,914
4,938
10,803
11,361
3,911
5,805
3,647
6,041
4,557
2,229
1,855
3,047
46,074
3,607
2,885
3,680
2,966
19,947
39,677
27,777
14,249
15,678
1,565
4,114
3,314
5,014
15,607
35,315
31,937
43,213
42,894
37,299
41,205
36,802
42,031
47,245
42,925
38,889
29,156
28,871
28,994
22,492
30,220
10,006
11,532
5,981
2,995
1,335
2,204
2,252
2,2522,2041,3352,9955,98111,53210,00630,22022,49228,99428,87129,15638,88942,92547,24542,03136,80241,20537,29942,89443,21331,93735,31515,6075,0143,3144,1141,56515,67814,24927,77739,67719,9472,9663,6802,8853,60746,0743,0471,8552,2294,5576,0413,6475,8053,91111,36110,8034,93812,9148,4602,16025,1025,5539,4467,7094,8016,3308,4735,79611,1618,51512,06714,04021,63736,80549,82964,74747,14837,83872,48717,4328,20514,55110,4486,33312,8425,64318,9443,5636,1538,7248,8476,7754,3703,7104,8484,4874,4875,32110,3903,3337,2341,9422,3216821,7561,16713,6320000005,0005,0000000000000000
       Other Current Assets 
3,200
7,400
10,100
4,300
5,900
17,200
19,200
16,600
16,300
27,500
24,500
18,900
887
1,797
1,699
752
3,140
2,252
1,673
1,678
3,231
538
4,938
7,377
7,883
5,377
5,788
968
7,683
1,903
7,475
8,798
8,798
8,927
7,139
6,341
6,326
6,970
6,307
5,819
18,800
6,758
7,710
12,266
10,528
9,546
10,178
16,810
19,238
8,072
7,023
14,595
11,733
9,520
8,147
7,106
5,826
13,988
47,395
6,746
6,108
5,317
7,275
6,183
7,101
6,363
6,119
5,679
6,859
7,932
7,565
17,944
13,634
9,341
7,003
13,363
8,813
6,018
4,759
5,175
5,972
4,629
4,708
8,817
6,092
8,782
5,214
9,814
5,593
5,427
4,008
10,363
7,881
7,496
13,260
14,948
13,074
34,940
12,540
21,293
19,352
13,213
15,212
15,387
13,811
37,770
21,550
18,020
15,771
12,596
20,731
23,333
20,831
19,245
22,507
15,808
11,009
9,602
9,033
8,732
8,7329,0339,60211,00915,80822,50719,24520,83123,33320,73112,59615,77118,02021,55037,77013,81115,38715,21213,21319,35221,29312,54034,94013,07414,94813,2607,4967,88110,3634,0085,4275,5939,8145,2148,7826,0928,8174,7084,6295,9725,1754,7596,0188,81313,3637,0039,34113,63417,9447,5657,9326,8595,6796,1196,3637,1016,1837,2755,3176,1086,74647,39513,9885,8267,1068,1479,52011,73314,5957,0238,07219,23816,81010,1789,54610,52812,2667,7106,75818,8005,8196,3076,9706,3266,3417,1398,9278,7988,7987,4751,9037,6839685,7885,3777,8837,3774,9385383,2311,6781,6732,2523,1407521,6991,79788718,90024,50027,50016,30016,60019,20017,2005,9004,30010,1007,4003,200
   > Long-term Assets 
1,700
1,600
2,400
2,400
2,600
2,600
2,700
2,800
3,000
3,200
3,700
4,000
4,345
6,836
10,490
18,837
26,893
33,510
38,062
49,956
54,542
54,229
56,903
79,488
104,009
117,216
131,681
136,497
222,246
321,011
316,231
0
306,400
302,715
297,137
295,649
293,507
304,843
306,084
310,290
297,362
299,628
290,363
290,382
285,345
282,773
288,701
338,711
292,172
254,419
243,588
233,138
222,163
220,099
223,514
201,820
200,313
199,365
158,065
154,316
155,344
154,795
154,438
161,852
163,038
166,832
176,042
167,246
165,105
281,759
350,473
329,844
274,135
200,152
194,507
183,159
180,865
178,386
175,093
176,645
182,243
179,914
152,782
153,421
151,919
154,421
162,895
152,010
147,034
144,779
142,573
142,619
147,501
187,694
199,260
182,046
160,775
407,140
743,916
712,485
676,368
502,836
509,470
555,806
458,609
442,910
464,810
400,762
357,510
315,203
291,108
321,608
290,661
196,451
181,523
164,632
70,677
53,221
43,219
67,332
67,33243,21953,22170,677164,632181,523196,451290,661321,608291,108315,203357,510400,762464,810442,910458,609555,806509,470502,836676,368712,485743,916407,140160,775182,046199,260187,694147,501142,619142,573144,779147,034152,010162,895154,421151,919153,421152,782179,914182,243176,645175,093178,386180,865183,159194,507200,152274,135329,844350,473281,759165,105167,246176,042166,832163,038161,852154,438154,795155,344154,316158,065199,365200,313201,820223,514220,099222,163233,138243,588254,419292,172338,711288,701282,773285,345290,382290,363299,628297,362310,290306,084304,843293,507295,649297,137302,715306,4000316,231321,011222,246136,497131,681117,216104,00979,48856,90354,22954,54249,95638,06233,51026,89318,83710,4906,8364,3454,0003,7003,2003,0002,8002,7002,6002,6002,4002,4001,6001,700
       Property Plant Equipment 
1,500
1,500
2,200
2,300
2,400
2,500
2,600
2,700
2,800
3,100
3,500
3,800
4,210
6,701
10,355
18,694
26,750
33,408
37,918
49,863
54,449
54,136
56,810
63,852
76,066
91,065
101,472
110,457
119,867
133,341
138,837
142,352
142,352
144,031
142,191
143,452
142,706
143,439
145,037
149,388
154,023
157,615
150,009
151,247
147,726
146,371
144,716
142,127
140,301
139,152
136,580
133,812
132,345
131,024
135,317
114,420
114,381
114,229
73,641
73,578
75,020
75,024
74,624
78,263
82,650
88,223
97,686
89,773
87,628
85,381
81,649
78,576
75,557
73,713
73,256
72,215
70,112
67,849
65,082
66,974
72,968
71,070
69,275
70,368
69,267
72,158
72,532
71,336
69,852
67,774
65,553
65,601
66,642
64,929
62,396
47,463
46,328
45,000
44,881
48,851
141,633
147,630
199,502
199,176
196,208
192,830
189,174
186,138
183,481
180,961
178,544
177,535
175,276
108,788
102,699
85,886
69,271
51,569
38,696
36,863
36,86338,69651,56969,27185,886102,699108,788175,276177,535178,544180,961183,481186,138189,174192,830196,208199,176199,502147,630141,63348,85144,88145,00046,32847,46362,39664,92966,64265,60165,55367,77469,85271,33672,53272,15869,26770,36869,27571,07072,96866,97465,08267,84970,11272,21573,25673,71375,55778,57681,64985,38187,62889,77397,68688,22382,65078,26374,62475,02475,02073,57873,641114,229114,381114,420135,317131,024132,345133,812136,580139,152140,301142,127144,716146,371147,726151,247150,009157,615154,023149,388145,037143,439142,706143,452142,191144,031142,352142,352138,837133,341119,867110,457101,47291,06576,06663,85256,81054,13654,44949,86337,91833,40826,75018,69410,3556,7014,2103,8003,5003,1002,8002,7002,6002,5002,4002,3002,2001,5001,500
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
131,588
133,856
132,021
130,120
130,120
130,120
130,120
130,120
130,120
130,120
130,120
130,120
130,120
129,986
129,986
129,986
78,431
78,431
78,431
78,431
78,431
78,431
78,431
78,431
78,431
78,431
78,431
78,431
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
0
0
0
0
000076,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50178,43178,43178,43178,43178,43178,43178,43178,43178,43178,43178,43178,431129,986129,986129,986130,120130,120130,120130,120130,120130,120130,120130,120130,120130,120132,021133,856131,5880000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
118,941
191,478
173,768
116,732
44,245
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,493
45,160
59,596
57,088
37,157
282,277
619,140
582,889
455,867
276,305
231,082
279,119
185,900
172,166
197,715
136,662
96,093
57,397
34,219
64,828
37,363
8,928
0
0
0
0
0
25,825
25,825000008,92837,36364,82834,21957,39796,093136,662197,715172,166185,900279,119231,082276,305455,867582,889619,140282,27737,15757,08859,59645,1603,49300000000000000000044,245116,732173,768191,478118,941000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87,888
171,006
162,631
153,833
153,833
149,744
146,716
145,590
144,463
143,336
142,209
141,083
139,956
138,829
137,702
136,576
135,314
134,188
133,061
91,883
11,944
10,539
9,831
3,626
3,390
3,153
2,917
2,680
2,444
2,207
1,971
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
76,501
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000076,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,50176,5011,9712,2072,4442,6802,9173,1533,3903,6269,83110,53911,94491,883133,061134,188135,314136,576137,702138,829139,956141,083142,209143,336144,463145,590146,716149,744153,833153,833162,631171,00687,8880000000000000000000000000000
       Long-term Assets Other 
200
100
200
100
200
100
100
100
200
100
200
200
135
135
135
143
143
102
144
93
93
93
93
15,636
27,943
26,151
30,209
16,900
14,491
16,664
14,763
10,215
10,215
8,940
8,230
6,607
6,338
18,068
18,838
19,819
3,383
3,184
2,652
2,559
2,305
2,214
10,924
104,701
61,496
26,297
18,746
17,269
7,997
7,491
6,849
6,289
5,057
4,498
4,022
4,237
3,823
3,270
3,313
7,088
3,887
2,108
1,855
972
976
936
845
999
5,345
5,693
44,750
34,443
34,252
34,036
33,510
33,170
32,774
32,343
7,006
6,552
6,151
5,762
13,862
4,173
681
504
519
517
865
1,104
767
994
789
3,362
3,394
4,244
2,367
2,400
2,385
1,010
133,901
1,413
1,420
1,461
1,435
344
1,844
2,744
1,521
2,234
2,323
2,245
1,406
1,652
4,523
4,644
4,6444,5231,6521,4062,2452,3232,2341,5212,7441,8443441,4351,4611,4201,413133,9011,0102,3852,4002,3674,2443,3943,3627899947671,1048655175195046814,17313,8625,7626,1516,5527,00632,34332,77433,17033,51034,03634,25234,44344,7505,6935,3459998459369769721,8552,1083,8877,0883,3133,2703,8234,2374,0224,4985,0576,2896,8497,4917,99717,26918,74626,29761,496104,70110,9242,2142,3052,5592,6523,1843,38319,81918,83818,0686,3386,6078,2308,94010,21510,21514,76316,66414,49116,90030,20926,15127,94315,63693939393144102143143135135135200200100200100100100200100200100200
> Total Liabilities 
2,100
2,200
2,600
1,800
3,000
2,700
2,600
3,000
2,900
3,300
3,500
6,400
9,390
12,787
15,003
22,669
20,344
18,834
16,174
18,615
20,571
21,606
22,224
140,177
278,417
275,065
266,156
351,657
366,611
393,863
383,100
396,928
396,928
394,833
389,885
399,868
376,609
459,824
474,331
452,597
276,196
263,558
260,963
277,579
270,182
272,731
512,806
531,743
534,732
561,884
538,337
541,117
503,117
514,785
567,382
510,664
468,077
465,792
459,720
370,382
346,665
342,400
346,551
473,151
443,755
421,109
395,529
430,563
423,240
419,578
417,296
408,739
532,302
536,159
446,120
450,772
450,521
453,358
433,285
524,430
496,822
513,497
429,684
405,289
421,907
421,568
410,193
495,632
492,154
502,350
492,948
480,746
483,737
472,473
497,893
421,038
438,507
452,673
458,976
432,597
532,971
542,498
599,583
571,965
591,507
338,638
337,685
461,472
462,055
466,376
475,703
437,681
416,227
403,255
368,783
343,962
320,878
297,321
282,876
267,046
267,046282,876297,321320,878343,962368,783403,255416,227437,681475,703466,376462,055461,472337,685338,638591,507571,965599,583542,498532,971432,597458,976452,673438,507421,038497,893472,473483,737480,746492,948502,350492,154495,632410,193421,568421,907405,289429,684513,497496,822524,430433,285453,358450,521450,772446,120536,159532,302408,739417,296419,578423,240430,563395,529421,109443,755473,151346,551342,400346,665370,382459,720465,792468,077510,664567,382514,785503,117541,117538,337561,884534,732531,743512,806272,731270,182277,579260,963263,558276,196452,597474,331459,824376,609399,868389,885394,833396,928396,928383,100393,863366,611351,657266,156275,065278,417140,17722,22421,60620,57118,61516,17418,83420,34422,66915,00312,7879,3906,4003,5003,3002,9003,0002,6002,7003,0001,8002,6002,2002,100
   > Total Current Liabilities 
1,500
1,700
2,100
1,400
2,400
2,400
2,400
2,700
2,500
3,100
3,300
6,200
9,215
12,625
14,615
17,114
14,642
13,081
10,368
12,756
14,657
15,631
16,028
25,079
31,948
30,498
21,519
30,203
39,472
58,746
44,912
59,199
59,199
57,835
50,910
63,665
41,124
44,894
48,802
46,857
49,538
45,242
38,453
55,653
51,491
54,544
47,825
69,595
110,301
114,837
95,329
165,314
111,476
121,327
156,679
98,092
57,645
58,760
48,522
68,374
46,637
45,316
49,357
153,016
125,645
107,466
84,832
64,108
58,880
61,274
279,042
275,532
270,753
276,861
69,470
78,537
83,221
90,277
80,913
98,221
79,313
84,355
80,549
64,047
75,444
81,077
208,098
61,246
65,945
79,282
76,305
72,222
78,515
72,613
92,544
56,163
80,697
96,897
108,083
82,002
99,718
113,370
125,350
353,893
377,471
123,958
126,500
115,779
123,633
131,023
139,969
85,200
105,281
104,985
83,989
68,204
59,879
50,694
52,112
51,269
51,26952,11250,69459,87968,20483,989104,985105,28185,200139,969131,023123,633115,779126,500123,958377,471353,893125,350113,37099,71882,002108,08396,89780,69756,16392,54472,61378,51572,22276,30579,28265,94561,246208,09881,07775,44464,04780,54984,35579,31398,22180,91390,27783,22178,53769,470276,861270,753275,532279,04261,27458,88064,10884,832107,466125,645153,01649,35745,31646,63768,37448,52258,76057,64598,092156,679121,327111,476165,31495,329114,837110,30169,59547,82554,54451,49155,65338,45345,24249,53846,85748,80244,89441,12463,66550,91057,83559,19959,19944,91258,74639,47230,20321,51930,49831,94825,07916,02815,63114,65712,75610,36813,08114,64217,11414,61512,6259,2156,2003,3003,1002,5002,7002,4002,4002,4001,4002,1001,7001,500
       Short-term Debt 
200
200
200
200
0
0
0
200
0
0
0
200
0
0
0
83
0
0
0
64
0
0
0
45
0
0
0
1,018
977
977
977
807
807
904
956
1,008
1,062
1,118
5,792
1,629
1,743
1,469
1,651
1,547
1,701
408
444
482
36,547
36,588
36,630
103,364
67,387
67,438
67,761
2,335
2,259
1,833
1,401
39,115
32,060
26,194
29,855
28,573
25,027
31,446
35,721
29,936
30,560
31,396
214,955
214,955
214,955
214,955
32,337
41,364
43,097
46,295
43,087
44,319
33,141
37,325
34,323
4,512
5,412
5,643
130,883
4,756
4,782
3,616
2,370
2,908
2,909
2,706
2,482
31,986
49,686
58,145
78,303
61,763
1,649
3,749
9,318
261,209
269,757
15,139
15,348
13,915
15,768
16,776
17,740
17,441
19,597
20,047
18,508
18,667
18,773
18,933
19,095
19,259
19,25919,09518,93318,77318,66718,50820,04719,59717,44117,74016,77615,76813,91515,34815,139269,757261,2099,3183,7491,64961,76378,30358,14549,68631,9862,4822,7062,9092,9082,3703,6164,7824,756130,8835,6435,4124,51234,32337,32533,14144,31943,08746,29543,09741,36432,337214,955214,955214,955214,95531,39630,56029,93635,72131,44625,02728,57329,85526,19432,06039,1151,4011,8332,2592,33567,76167,43867,387103,36436,63036,58836,5474824444081,7011,5471,6511,4691,7431,6295,7921,1181,0621,0089569048078079779779771,018000450006400083000200000200000200200200200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
133,651
0
0
0
247,528
4,782
3,616
2,370
243,464
2,909
248,098
247,253
245,207
245,643
246,078
0
0
1,649
0
0
248,693
254,144
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000254,144248,693001,64900246,078245,643245,207247,253248,0982,909243,4642,3703,6164,782247,528000133,65100000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
600
700
1,500
300
900
1,200
1,200
700
1,200
1,600
1,500
1,100
2,987
5,160
5,038
5,975
7,899
9,161
5,308
3,678
10,902
12,468
11,812
13,374
23,737
21,889
17,158
6,501
28,351
38,724
36,161
7,685
7,685
6,929
5,198
8,655
6,593
4,903
6,522
8,074
9,362
5,069
4,708
7,141
5,117
8,461
8,708
18,895
14,633
9,772
6,761
8,160
3,658
2,941
4,421
3,589
1,556
1,862
2,113
13,832
2,675
4,931
6,397
3,066
5,664
4,627
4,403
7,194
3,481
3,243
2,175
3,019
1,761
3,118
2,624
2,863
4,218
5,572
3,723
9,115
3,064
7,437
5,428
2,703
5,024
2,833
2,279
2,363
2,349
2,328
7,118
2,816
6,951
6,241
8,563
4,782
11,375
10,674
7,494
5,854
11,012
9,346
21,963
19,234
21,789
19,246
15,484
22,139
22,434
19,701
23,660
9,747
12,617
12,346
5,329
12,980
3,696
2,619
3,288
9,848
9,8483,2882,6193,69612,9805,32912,34612,6179,74723,66019,70122,43422,13915,48419,24621,78919,23421,9639,34611,0125,8547,49410,67411,3754,7828,5636,2416,9512,8167,1182,3282,3492,3632,2792,8335,0242,7035,4287,4373,0649,1153,7235,5724,2182,8632,6243,1181,7613,0192,1753,2433,4817,1944,4034,6275,6643,0666,3974,9312,67513,8322,1131,8621,5563,5894,4212,9413,6588,1606,7619,77214,63318,8958,7088,4615,1177,1414,7085,0699,3628,0746,5224,9036,5938,6555,1986,9297,6857,68536,16138,72428,3516,50117,15821,88923,73713,37411,81212,46810,9023,6785,3089,1617,8995,9755,0385,1602,9871,1001,5001,6001,2007001,2001,2009003001,500700600
       Other Current Liabilities 
700
800
400
900
1,500
1,200
1,200
1,800
1,300
1,500
1,800
4,900
1,037
1,257
1,069
4,370
0
0
0
4,655
0
0
0
6,849
8,211
8,609
4,361
17,771
10,144
19,045
17,771
50,707
33,634
29,346
28,343
31,962
25,147
24,553
21,219
18,435
16,650
17,025
16,024
17,075
15,968
17,911
16,906
34,731
41,991
50,771
33,872
37,381
31,796
37,186
40,861
72,548
34,173
38,012
33,038
5,417
3,486
5,421
3,558
5,814
4,489
6,051
4,476
6,394
4,865
6,768
41,930
37,915
34,030
38,097
11,870
12,414
12,667
16,297
12,803
21,123
19,566
14,827
16,172
32,359
40,049
49,614
54,325
32,699
41,574
57,323
52,716
52,146
44,463
50,293
56,008
446
105
10,090
6,610
493
75,965
90,383
85,677
67,933
82,918
87,816
95,161
79,634
85,431
94,546
98,569
58,012
73,067
72,592
60,152
36,557
37,410
29,142
29,729
22,162
22,16229,72929,14237,41036,55760,15272,59273,06758,01298,56994,54685,43179,63495,16187,81682,91867,93385,67790,38375,9654936,61010,09010544656,00850,29344,46352,14652,71657,32341,57432,69954,32549,61440,04932,35916,17214,82719,56621,12312,80316,29712,66712,41411,87038,09734,03037,91541,9306,7684,8656,3944,4766,0514,4895,8143,5585,4213,4865,41733,03838,01234,17372,54840,86137,18631,79637,38133,87250,77141,99134,73116,90617,91115,96817,07516,02417,02516,65018,43521,21924,55325,14731,96228,34329,34633,63450,70717,77119,04510,14417,7714,3618,6098,2116,8490004,6550004,3701,0691,2571,0374,9001,8001,5001,3001,8001,2001,2001,500900400800700
   > Long-term Liabilities 
600
500
500
400
600
300
200
300
400
200
200
200
175
162
388
5,555
5,702
5,753
5,806
5,859
5,914
5,975
6,196
115,098
246,469
244,567
244,637
321,454
327,139
335,117
338,188
0
337,729
336,998
338,975
336,203
335,485
414,930
425,529
405,740
226,658
218,316
222,510
221,926
218,691
218,187
464,981
462,148
424,431
447,047
443,008
375,803
391,641
393,458
410,703
412,572
410,432
407,032
411,198
302,008
300,028
297,084
297,194
320,135
318,110
313,643
310,697
366,455
364,360
358,304
138,254
133,207
261,549
259,298
376,650
372,235
367,300
363,081
352,372
426,209
417,509
429,142
349,135
341,242
346,463
340,491
202,095
434,386
426,209
423,068
416,643
408,524
405,222
399,860
405,349
364,875
357,810
355,776
350,893
350,595
433,253
429,128
474,233
218,072
214,036
214,680
211,185
345,693
338,422
335,353
335,734
352,481
310,946
298,270
284,794
275,758
260,999
246,627
230,764
215,777
215,777230,764246,627260,999275,758284,794298,270310,946352,481335,734335,353338,422345,693211,185214,680214,036218,072474,233429,128433,253350,595350,893355,776357,810364,875405,349399,860405,222408,524416,643423,068426,209434,386202,095340,491346,463341,242349,135429,142417,509426,209352,372363,081367,300372,235376,650259,298261,549133,207138,254358,304364,360366,455310,697313,643318,110320,135297,194297,084300,028302,008411,198407,032410,432412,572410,703393,458391,641375,803443,008447,047424,431462,148464,981218,187218,691221,926222,510218,316226,658405,740425,529414,930335,485336,203338,975336,998337,7290338,188335,117327,139321,454244,637244,567246,469115,0986,1965,9755,9145,8595,8065,7535,7025,555388162175200200200400300200300600400500500600
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
231,403
230,818
15,250
14,582
13,890
13,174
137,414
136,607
135,766
134,901
134,007
133,049
132,050
131,025
130,339
129,139
129,386
127,889
1,335
243,188
245,455
245,323
245,147
245,687
245,509
245,392
244,771
245,207
245,643
246,078
246,514
246,950
247,386
247,821
248,257
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000248,257247,821247,386246,950246,514246,078245,643245,207244,771245,392245,509245,687245,147245,323245,455243,1881,335127,889129,386129,139130,339131,025132,050133,049134,007134,901135,766136,607137,41413,17413,89014,58215,250230,818231,40300000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,824
1,931
2,010
2,187
9,199
9,633
9,428
6,671
6,338
6,045
7,485
5,192
4,848
5,238
6,337
14,066
13,879
13,895
24,813
13,860
24,092
23,702
26,909
22,847
22,675
45,445
41,567
41,044
57,093
59,130
73,716
75,940
74,102
71,016
75,509
66,706
65,084
62,513
63,011
86,380
84,803
80,801
78,340
134,486
132,957
127,486
123,004
118,625
121,874
118,438
112,490
107,362
109,118
104,106
93,198
171,640
164,325
176,686
98,304
91,632
95,519
90,631
79,613
72,166
66,123
66,155
62,603
56,887
55,782
52,571
62,184
25,013
112,167
109,698
104,379
103,645
90,843
86,485
80,877
75,342
71,739
73,047
72,163
209,320
203,866
203,695
207,016
226,745
188,308
178,855
168,649
162,929
0
140,810
0
0
00140,8100162,929168,649178,855188,308226,745207,016203,695203,866209,32072,16373,04771,73975,34280,87786,48590,843103,645104,379109,698112,16725,01362,18452,57155,78256,88762,60366,15566,12372,16679,61390,63195,51991,63298,304176,686164,325171,64093,198104,106109,118107,362112,490118,438121,874118,625123,004127,486132,957134,48678,34080,80184,80386,38063,01162,51365,08466,70675,50971,01674,10275,94073,71659,13057,09341,04441,56745,44522,67522,84726,90923,70224,09213,86024,81313,89513,87914,0666,3375,2384,8485,1927,4856,0456,3386,6719,4289,6339,1992,1872,0101,9311,824000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
126,752
121,646
116,542
111,466
111,050
108,215
101,762
98,955
100,103
95,483
83,981
82,384
76,549
88,918
82,902
76,911
78,418
73,963
68,941
62,426
59,587
60,135
57,088
51,887
51,666
48,979
56,225
19,021
12,808
0
0
0
0
0
0
0
0
0
0
0
4,597
11,607
21,387
0
0
0
0
0
0
0
0
0
00000000021,38711,6074,5970000000000012,80819,02156,22548,97951,66651,88757,08860,13559,58762,42668,94173,96378,41876,91182,90288,91876,54982,38483,98195,483100,10398,955101,762108,215111,050111,466116,542121,646126,75200000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
5,000
18,700
17,700
15,400
25,500
24,000
22,400
20,200
18,300
35,400
33,300
35,100
63,627
62,015
59,845
97,093
93,529
91,233
86,425
115,881
110,778
105,082
99,145
86,629
169,875
159,296
154,169
277,883
320,532
328,832
302,583
270,313
270,313
262,172
236,649
206,770
187,335
174,672
158,594
164,191
510,939
497,361
480,140
467,342
444,010
421,324
434,104
326,811
306,806
265,261
251,683
227,060
210,623
188,680
170,903
214,439
175,759
143,701
108,632
190,154
159,274
130,598
106,100
102,367
104,754
109,529
106,947
90,662
281,238
251,276
230,797
197,811
162,487
132,284
95,332
47,018
-2,620
-40,549
-50,250
-89,903
-9,809
-35,360
47,218
36,332
77,305
35,099
39,053
6,429
-275
-39,251
-67,853
88,125
44,749
3,386
84,162
87,828
58,283
1,860,414
1,790,122
1,717,575
1,633,511
1,557,155
1,488,711
1,405,391
1,296,426
1,256,240
1,170,981
1,077,295
994,506
904,975
801,540
679,508
607,889
458,732
412,223
366,638
240,865
196,958
159,368
130,987
130,987159,368196,958240,865366,638412,223458,732607,889679,508801,540904,975994,5061,077,2951,170,9811,256,2401,296,4261,405,3911,488,7111,557,1551,633,5111,717,5751,790,1221,860,41458,28387,82884,1623,38644,74988,125-67,853-39,251-2756,42939,05335,09977,30536,33247,218-35,360-9,809-89,903-50,250-40,549-2,62047,01895,332132,284162,487197,811230,797251,276281,23890,662106,947109,529104,754102,367106,100130,598159,274190,154108,632143,701175,759214,439170,903188,680210,623227,060251,683265,261306,806326,811434,104421,324444,010467,342480,140497,361510,939164,191158,594174,672187,335206,770236,649262,172270,313270,313302,583328,832320,532277,883154,169159,296169,87586,62999,145105,082110,778115,88186,42591,23393,52997,09359,84562,01563,62735,10033,30035,40018,30020,20022,40024,00025,50015,40017,70018,7005,000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
93,415
94,055
94,529
135,273
135,924
136,578
1,569
2
2
2
2
2
2
2
4
5
5
5
5
5
5
6
6
6
6
6
6
6
8
8
8
8
8
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
11
11
11
11
11
11
11
11
11
11
11
11
12
12
12
13
13
13
13
13
13
13
13
15
15
15
15
15
16
17
17
17
17
17
17
17
17
18
18
18
18
18
18
19
19
19
19
19
19
19
19
19
1919191919191919191818181818181717171717171717161515151515131313131313131312121211111111111111111111111199999999999999999999999888886666666555555422222221,569136,578135,924135,27394,52994,05593,415000000000000
   Retained Earnings -3,477,249-3,435,170-3,389,333-3,338,211-3,201,193-3,141,505-3,082,456-2,923,388-2,832,995-2,687,350-2,557,644-2,432,125-2,309,158-2,191,955-2,083,369-2,003,369-1,864,718-1,751,280-1,652,472-1,542,563-1,424,051-1,325,839-1,229,696-2,201,156-2,117,941-2,084,115-2,144,986-2,085,115-2,021,010-1,978,811-1,935,587-1,886,984-1,867,486-1,813,349-1,805,146-1,752,489-1,786,309-1,740,626-1,811,231-1,778,594-1,732,393-1,684,734-1,668,191-1,625,443-1,570,380-1,517,454-1,473,907-1,439,622-1,398,525-1,361,030-1,336,962-1,300,581-1,264,547-1,241,967-1,233,256-1,232,739-1,226,609-1,218,933-1,187,966-1,155,897-1,124,090-1,200,872-1,163,834-1,130,459-1,089,754-1,128,797-1,110,176-1,082,666-1,056,993-1,018,138-998,534-935,703-902,232-793,993-770,198-743,286-717,121-697,851-677,399-655,235-596,027-599,539-582,333-569,294-549,345-518,271-491,750-441,877-441,877-405,625-378,704-272,910-191,869-152,260-139,045-123,298-94,466-74,290-67,246-61,241-56,018-49,732-44,690-41,817-37,642-34,684-32,033-29,741-27,700-24,400-22,200-19,700-17,800-15,500-13,900-12,300-10,100-7,800-6,900-6,000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,580,990
1,587,461
1,592,803
1,597,428
1,602,141
1,606,800
1,612,620
1,617,744
1,623,207
1,628,967
1,636,162
1,643,660
1,769,713
1,776,746
1,789,010
1,824,195
1,831,057
1,841,730
1,854,210
1,876,072
1,888,531
1,898,342
1,912,907
2,111,483
2,131,698
2,150,019
2,170,169
2,207,865
2,262,219
3,094,095
3,121,322
3,147,925
3,178,773
3,210,398
3,241,160
3,271,097
3,306,655
3,338,876
3,363,998
3,388,730
3,429,734
3,466,001
3,492,435
3,516,641
3,537,790
3,549,360
3,561,878
0
3,584,738
3,592,722
0
0
003,592,7223,584,73803,561,8783,549,3603,537,7903,516,6413,492,4353,466,0013,429,7343,388,7303,363,9983,338,8763,306,6553,271,0973,241,1603,210,3983,178,7733,147,9253,121,3223,094,0952,262,2192,207,8652,170,1692,150,0192,131,6982,111,4831,912,9071,898,3421,888,5311,876,0721,854,2101,841,7301,831,0571,824,1951,789,0101,776,7461,769,7131,643,6601,636,1621,628,9671,623,2071,617,7441,612,6201,606,8001,602,1411,597,4281,592,8031,587,4611,580,99000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
11,000
25,600
25,500
26,400
38,700
38,800
38,800
39,700
39,700
59,300
59,400
65,600
2,753
2,793
2,800
4,642
5,321
5,970
142,091
180,492
181,769
183,081
185,479
196,102
309,026
316,552
326,326
491,473
615,163
729,257
729,929
0
750,151
713,239
713,737
714,680
715,273
715,790
808,456
819,569
1,225,523
1,234,109
1,237,340
1,248,123
1,188,288
1,192,513
1,229,088
1,231,034
1,244,500
1,264,786
1,356,556
1,390,642
1,399,878
1,405,445
1,298,691
1,302,184
1,304,209
1,306,526
1,415,746
1,313,235
1,315,162
1,317,555
1,324,024
1,327,967
1,336,484
1,341,776
1,347,905
1,354,200
1,580,808
1,587,227
1,592,816
1,597,325
1,602,098
1,607,180
1,612,775
1,690,053
1,622,812
1,628,631
1,636,473
1,643,479
1,769,773
1,776,859
1,788,832
1,824,628
1,830,781
1,841,232
1,854,389
1,875,902
1,888,696
1,898,323
1,912,945
2,111,120
2,131,849
2,150,357
2,170,262
2,207,754
2,262,423
3,094,093
3,120,944
3,147,609
3,179,057
3,210,610
3,240,974
3,271,092
3,306,778
3,338,591
3,363,918
3,388,730
3,429,734
3,466,001
3,492,435
3,516,641
3,537,790
3,549,360
3,561,878
3,574,719
3,584,738
3,592,722
3,600,871
3,608,137
3,608,1373,600,8713,592,7223,584,7383,574,7193,561,8783,549,3603,537,7903,516,6413,492,4353,466,0013,429,7343,388,7303,363,9183,338,5913,306,7783,271,0923,240,9743,210,6103,179,0573,147,6093,120,9443,094,0932,262,4232,207,7542,170,2622,150,3572,131,8492,111,1201,912,9451,898,3231,888,6961,875,9021,854,3891,841,2321,830,7811,824,6281,788,8321,776,8591,769,7731,643,4791,636,4731,628,6311,622,8121,690,0531,612,7751,607,1801,602,0981,597,3251,592,8161,587,2271,580,8081,354,2001,347,9051,341,7761,336,4841,327,9671,324,0241,317,5551,315,1621,313,2351,415,7461,306,5261,304,2091,302,1841,298,6911,405,4451,399,8781,390,6421,356,5561,264,7861,244,5001,231,0341,229,0881,192,5131,188,2881,248,1231,237,3401,234,1091,225,523819,569808,456715,790715,273714,680713,737713,239750,1510729,929729,257615,163491,473326,326316,552309,026196,102185,479183,081181,769180,492142,0915,9705,3214,6422,8002,7932,75365,60059,40059,30039,70039,70038,80038,80038,70026,40025,50025,60011,000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue90,122
Cost of Revenue-36,644
Gross Profit53,47853,478
 
Operating Income (+$)
Gross Profit53,478
Operating Expense-190,903
Operating Income-137,425-137,425
 
Operating Expense (+$)
Research Development111,286
Selling General Administrative77,417
Selling And Marketing Expenses2,200
Operating Expense190,903190,903
 
Net Interest Income (+$)
Interest Income17,618
Interest Expense-25,334
Other Finance Cost-334
Net Interest Income-8,050
 
Pretax Income (+$)
Operating Income-137,425
Net Interest Income-8,050
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-276,2561,406
EBIT - interestExpense = -162,759
-276,256
-250,722
Interest Expense25,334
Earnings Before Interest and Taxes (EBIT)-137,425-250,922
Earnings Before Interest and Taxes (EBITDA)-129,610
 
After tax Income (+$)
Income Before Tax-276,256
Tax Provision-2,973
Net Income From Continuing Ops-293,665-279,229
Net Income-276,056
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses227,547
Total Other Income/Expenses Net-138,8318,050
 

Technical Analysis of Nektar
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nektar. The general trend of Nektar is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nektar's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nektar Therapeutics.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.75 < 1.99 < 2.19.

The bearish price targets are: 1.2 > 1.12 > 1.09.

Tweet this
Nektar Therapeutics Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nektar Therapeutics. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nektar Therapeutics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nektar Therapeutics. The current macd is 0.10437191.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nektar price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Nektar. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Nektar price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Nektar Therapeutics Daily Moving Average Convergence/Divergence (MACD) ChartNektar Therapeutics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nektar Therapeutics. The current adx is 39.61.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Nektar shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Nektar Therapeutics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nektar Therapeutics. The current sar is 1.67746904.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Nektar Therapeutics Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nektar Therapeutics. The current rsi is 61.48. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Nektar Therapeutics Daily Relative Strength Index (RSI) ChartNektar Therapeutics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nektar Therapeutics. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nektar price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Nektar Therapeutics Daily Stochastic Oscillator ChartNektar Therapeutics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nektar Therapeutics. The current cci is 59.98.

Nektar Therapeutics Daily Commodity Channel Index (CCI) ChartNektar Therapeutics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nektar Therapeutics. The current cmo is 22.09.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Nektar Therapeutics Daily Chande Momentum Oscillator (CMO) ChartNektar Therapeutics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nektar Therapeutics. The current willr is -52.72727273.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Nektar is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Nektar Therapeutics Daily Williams %R ChartNektar Therapeutics Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nektar Therapeutics.

Nektar Therapeutics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nektar Therapeutics. The current atr is 0.13616935.

Nektar Therapeutics Daily Average True Range (ATR) ChartNektar Therapeutics Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nektar Therapeutics. The current obv is 522,554.

Nektar Therapeutics Daily On-Balance Volume (OBV) ChartNektar Therapeutics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nektar Therapeutics. The current mfi is 61.95.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Nektar Therapeutics Daily Money Flow Index (MFI) ChartNektar Therapeutics Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nektar Therapeutics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-17MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Nektar Therapeutics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nektar Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.485
Ma 20Greater thanMa 501.374
Ma 50Greater thanMa 1001.051
Ma 100Greater thanMa 2000.805
OpenGreater thanClose1.450
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nektar with someone you think should read this too:
  • Are you bullish or bearish on Nektar? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nektar? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nektar Therapeutics

I send you an email if I find something interesting about Nektar Therapeutics.


Comments

How you think about this?

Leave a comment

Stay informed about Nektar Therapeutics.

Receive notifications about Nektar Therapeutics in your mailbox!